Table 1 Baseline characteristics of rheumatoid arthritis patients by response to anti-TNF therapy at 6Â months
From: Variations in the metabolome in response to disease activity of rheumatoid arthritis
|  | Good responders (n = 100) | Non-responders (n = 40) | P-value |
|---|---|---|---|
Age, years (mean ± SD) | 50 ± 14 | 57 ± 13 | 0.44 |
Female (%) | 76 (76) | 31 (77.5) | 1.00 |
Disease duration (months, range) | 9 (3.3–15.3) | 10 (3.7–12.8) | 0.54 |
Infliximab (%) | 13 (13) | 7 (17) | 0.64 |
Adalimumab (%) | 29 (29) | 17 (43) | 0.32 |
Etanercept (%) | 58 (58) | 16 (40) | 0.82 |
DAS-28 M0 (Mean ± SD) | 4.8 ± 0.9 | 5.0 ± 1.2 | - |
DAS-28 M6 (Mean ± SD) | 2.2 ± 0.6 | 4.8 ± 1.2 | - |
RF positivity (%) | 77.4 | 70 | 0.25 |
ACPA positivity (%) | 75 | 62 | 0.18 |
ERS (mm/h) | 32 ± 25 | 35 ± 23 | 0.37 |
CRP (mg/l) | 17 ± 19 | 21 ± 18 | 0.45 |
Bone erosion (%) | 38 | 31 | 0.37 |